Journals | Policy | Permission

World Journal of Oncology

Case Report

Volume 5, Number 3, June 2014, pages 144-148

Primary Angiosarcoma of the Breast: A Case Report and Review of Literature

Angiosarcoma of the breast (ASB) is a rare tumor, accounting for less than 0.05% of all primary breast neoplasms [1, 2]. Primary angiosarcomas occur in women without any known risk factors, while secondary angiosarcomas are seen in the setting of previous breast irradiation or lymphedema (Stewart Treves syndrome) [3, 4]. Compared to secondary angiosarcomas, primary ASB tends to occur in younger women and are associated with higher incidence of distant metastases [5]. There is paucity of data on how to diagnose and manage these tumors.

A 32-year-old woman with no significant past medical history, other than history of bilateral reduction mammoplasty (14 years prior) presented with a non-tender lump in her right breast. She denied any nipple discharge, changes in overlying skin or any other lumps. She was not on any medications, but had an intra-uterine contraceptive device. She reported a history of rectal cancer in her grandmother, but her personal and family history was negative for any other malignancies.

A diagnostic mammogram showed dense breasts with multiple nodular densities with a well-circumscribed nodular density in the upper outer quadrant of the right breast (Fig. 1a). An ultrasound demonstrated innumerable cysts in both breasts, largest measuring 3.5 × 0.9 cm in size. She then underwent aspiration of the cyst, which revealed clear fluid. She required repeated aspirations; at the third recurrence, the cyst was excised. Gross examination revealed a multiloculated cyst, 1.7 cm in largest diameter. Histopathologically, the breast stroma demonstrated variably increased vasculature, and immunostains were negative for pankeratin but positive for CD31, confirming endothelial lining of the lesion. It was found to be negative for any malignancy and was reported as an angioma. The tissue was sent for a second opinion and a final diagnosis of low-grade angiosarcoma was made (Fig. 2).

Click for large image

Figure 1. (a) Mammogram reveals multiple cystic lesions. (b) MRI shows the entire right breast is filled with multiple cystic structures with internal loculations.

Click for large image

Figure 2. (a) Subtle vascular channels infiltrating the stroma, fat and even ductular tissue of the breast. (b) Higher magnification shows relatively bland vascular lesions but with an obviously infiltrating pattern throughout normal breast tissue.

MRI of the breast revealed multiple cystic structures in the entire right breast, majority of which contained internal loculations (Fig. 1b). There were no abnormalities noted in the left breast or axillary region. She then underwent a positron emission tomography/computerized tomography (PET/CT) scan which was negative except for some postoperative changes in the right breast.

Given the MRI findings that were highly suspicious for diffuse involvement of right breast with angiosarcoma and the natural history of ASB, the patient elected to undergo bilateral simple mastectomies. Pathology revealed benign breast tissue on the left side, and the right breast showed a poorly-delineated, multi-loculated, thin-walled cystic mass, approximately 5 × 4 × 4 cm in size. Low-grade angiosarcoma was identified in multiple sections from the lower outer quadrant and mid portion of the specimen. Microscopic tumor was present within 0.2 cm of the deep margin, and all other margins were negative. There was no evidence of lymphovascular invasion by the tumor. Post-operative treatment consisted of adjuvant chemo-therapy with paclitaxel on days 1, 8 and 15 of a 4-week cycle, for three cycles. This was followed by radiation therapy, 50 Gy with a boost to the scar with an additional 10 Gy.

ASB is a rare but aggressive neoplasm that affects women of all ages (range from 20 to 87 years) with peak incidence at 45 - 55 years [5, 6]. It is important to distinguish between primary and secondary ASB, and the latter most commonly presents as a violaceous rash and is associated with well-defined risk factors such as prior radiation therapy for breast cancer (relative risk of 15.9) [7] or lymphedema, the Stewart Treves syndrome [8]. Unlike secondary ASB that is usually cutaneous, by definition, primary ASB is a malignant vascular neoplasm that arises within the breast parenchyma, with or without extension into the overlying skin [9]. Primary ASB tends to occur in younger women (aged 20 - 40 years), with most patients presenting with a painless palpable lump. It is frequently missed on mammograms due to dense breasts in young women; this is especially true for low-grade angiosarcomas [10]. Breast ultrasound may show hyper- or hypo-echoic lesions with no acoustic shadowing although these findings are non-specific. On MRI, the tumor tends to have low intensity on T1-weighted and high intensity on T2-weighted images. These findings along with prolonged enhancement on dynamic study and multiple unenhanced areas within the tumor may be specific for ASB [11].

Histologically, ASB can be distinguished from invasive carcinomas (ductal/lobular) due to absence of cytokeratin and positive staining for vascular markers such as CD31, CD34. They need to be differentiated from other vascular tumors such as hemangiomas, angiolipomas and pseudoangiomatous stromal hyperplasia (PASH). Benign lesions tend to be well-circumscribed, with well-formed vascular channels; sarcomas have invasive features, a high mitotic rate and a high Ki-67, while PASH is negative for endothelial markers [9, 12]. However, misdiagnosis is common with a high percentage (up to 37%) of cases initially reported as benign [13, 14]. Painless breast tumors in young women that are highly vascular should be considered malignant unless proven otherwise [15, 16].

Tumors size is an important prognostic factor, with lesions more than 5 cm associated with distant metastasis [16], and the most common site is liver, followed by lung, lymph nodes and bones [16, 17] and even the heart [18]. Rosen et al demonstrated that histological grades are associated with prognosis: grade I (low), grade II (intermediate) and grade III (high) were associated with 76%, 70% and 15% 5-year disease free survival respectively [19]. However, grade has not been uniformly seen to affect survival [6] and a retrospective study of 41 cases showed no correlation between grade and risk of recurrence, metastasis or death [9].

Surgical resection of the tumor remains the mainstay of therapy while the role of multi-modality therapy is not clearly defined. Mastectomy is preferable to breast-conserving therapy and due to the rarity of nodal involvement, routine lymph node dissection is not recommended [20]. A recent paper that included both primary and secondary ASB concluded that breast-conservative surgery did not show a worse prognosis compared to mastectomy [21]. The margin status of the tumor is prognostically important in ASB (as in other sarcomas); positive margins are significantly associated with higher risk of local failure (P < 0.002) [22], although it has not consistently shown to be associated with worse overall survival [6, 22].

The role of adjuvant radiation therapy is generally supported by the literature. In a study of 59 patients with sarcoma of the breast, mastectomy followed by radiation therapy was associated with local failure rate of 13% compared to 34% without radiation therapy. This study could not show a statistical benefit for adjuvant radiation, this was attributed to limited sample size and the authors recommended post-mastectomy radiation for positive margins and large tumor size [22].

In a series reported by Anderson, adjuvant radio-therapy was associated with improved 5-year OS (47% vs. 33%) and recurrence free survival (24% vs. 20%); however, this was not statistically significant (P value 0.28 and 0.64 respectively) [17]. Another study on breast sarcomas showed a favorable outcome for conservative surgery and post-mastectomy radiation; however, only eight of the 78 patients had ASB [23].

The ANGIOTAX study was the first phase II prospective clinical trial of patients with metastatic or locally advanced angiosarcomas that established the role of weekly paclitaxel, ORR of 19% and non-progression rate of 24% at 6 months. However, this study included angiosarcomas of all sites that were not amenable to radiation or curative intent resection [24]. In a retrospective review of primary ASB, use of chemo-therapy was not associated with survival; however, an ORR of 48% was seen in metastatic ASB with combination cytotoxic chemo-therapy (anthracycline/ifosphamide or gemcitabine/taxane) [17]. Silverman et al reported that adjuvant chemo-therapy for patients with ASB results in significantly higher relapse free survival (29.2% vs. 4.4%, P < 0.05) [25]. The demonstration of diffuse expression of HIF-1α, WT-1 and VEGF in primary ASB, suggests that therapies directed against these targets should be evaluated [15].

This is the only reported case with a history of bilateral reduction mammoplasty, although there are case reports describing an association of augmentation mammoplasty and breast implants with various malignant tumors, including ASB [26-28]. However, a comprehensive review concluded that breast implants are not associated with an increased risk or a delay in detection of breast cancer [29]. Like many other reported cases, our patient was initially misdiagnosed as a benign tumor, but due to a high index of suspicion, a second opinion was sought and it clinched the diagnosis. Decision for radiation was based on size of tumor and the relatively narrow margin. The decision for adjuvant chemo-therapy was based on patient preference and the ANGIOTAX study led to the choice of paclitaxel. The patient tolerated the therapy well and was free of disease till l5.5 months after therapy when she was found to have an isolated, biopsy-proven metastasis to her liver. She is now being evaluated for resection of the metastatic lesion.

Primary ASB is a rare but aggressive tumor associated with a poor prognosis. There are limited data on management of these tumors and it is mostly derived from retrospective studies. Surgical resection with negative margins remains the mainstay of therapy and axillary dissection is not routinely recommended. The role of radiation therapy has been supported by multiple studies; however, data on the use of chemotherapy are sparse and extrapolated from treatment of angiosarcomas of all sites. Our case is the only reported case in literature of primary ASB in a patient with history of reduction mammoplasty and highlights the importance of using ultrasound and MRI in imaging. It further underscores the importance of maintaining a high index of suspicion for angiosarcomas in vascular lesions of the breast.

Conflict of Interest

Authors have no conflicts of interest to declare.

Abbreviations

ASB: angiosarcoma of breast; MRI: magnetic resonance imaging; PASH: pseudoangiomatous stromal hyperplasia; HIF-1α: hypoxia inducible factor-1α; WT-1: Wilms tumor-1; VEGF: vascular endothelial growth factor

1. Fraga-Guedes C, Gobbi H, Mastropasqua MG, Botteri E, Luini A, Viale G. Primary and secondary angiosarcomas of the breast: a single institution experience. Breast Cancer Res Treat. 2012;132(3):1081-1088.
   doi pubmed
2. Luini A, Gatti G, Diaz J, Botteri E, Oliveira E, Cecilio Sahium de Almeida R, Veronesi P, et al. Angiosarcoma of the breast: the experience of the European Institute of Oncology and a review of the literature. Breast Cancer Res Treat. 2007;105(1):81-85.
   doi pubmed
3. Yap J, Chuba PJ, Thomas R, Aref A, Lucas D, Severson RK, Hamre M. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2002;52(5):1231-1237.
   doi
4. Brady MS, Garfein CF, Petrek JA, Brennan MF. Post-treatment sarcoma in breast cancer patients. Ann Surg Oncol. 1994;1(1):66-72.
   doi pubmed
5. Vorburger SA, Xing Y, Hunt KK, Lakin GE, Benjamin RS, Feig BW, Pisters PW, et al. Angiosarcoma of the breast. Cancer. 2005;104(12):2682-2688.
   doi pubmed
6. Adem C, Reynolds C, Ingle JN, Nascimento AG. Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature. Br J Cancer. 2004;91(2):237-241.
   pubmed
7. Huang J, Mackillop WJ. Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer. 2001;92(1):172-180.
   doi
8. Stewart FW, Treves N. Lymphangiosarcoma in postmastectomy lymphedema; a report of six cases in elephantiasis chirurgica. Cancer. 1948;1(1):64-81.
   doi
9. Nascimento AF, Raut CP, Fletcher CD. Primary angiosarcoma of the breast: clinicopathologic analysis of 49 cases, suggesting that grade is not prognostic. Am J Surg Pathol. 2008;32(12):1896-1904.
   doi pubmed
10. Liberman L, Dershaw DD, Kaufman RJ, Rosen PP. Angiosarcoma of the breast. Radiology. 1992;183(3):649-654.
    pubmed
11. Kikawa Y, Konishi Y, Nakamoto Y, Harada T, Takeo M, Ogata M, Yamamoto M, et al. Angiosarcoma of the breast - specific findings of MRI. Breast Cancer. 2006;13(4):369-373.
    doi pubmed
12. Rosen PP. Rosen's Breast Pathology: Lippincott Williams & Wilkins; 2001.
13. Chen KT, Kirkegaard DD, Bocian JJ. Angiosarcoma of the breast. Cancer. 1980;46(2):368-371.
    doi
14. Rainwater LM, Martin JK Jr, Gaffey TA, van Heerden JA. Angiosarcoma of the breast. Arch Surg. 1986;121(6):669-672.
    doi pubmed
15. Al-Salam S, Balalaa N, Faour I, Akhter S, Alashari M. HIF-1alpha, VEGF and WT-1 are protagonists in bilateral primary angiosarcoma of breast: a case report and review of literature. Int J Clin Exp Pathol. 2012;5(3):247-253.
    pubmed
16. Desbiens C, Hogue JC, Levesque Y. Primary breast angiosarcoma: avoiding a common trap. Case Rep Oncol Med. 2011;2011:517047.
17. Sher T, Hennessy BT, Valero V, Broglio K, Woodward WA, Trent J, Hunt KK, et al. Primary angiosarcomas of the breast. Cancer. 2007;110(1):173-178.
    doi pubmed
18. Kim EK, Park IS, Sohn BS, Kim JE, Lee DH, Kim SW, Suh C. Angiosarcomas of the bilateral breast and heart: which one is the primary site?. Korean J Intern Med. 2012;27(2):224-228.
    doi pubmed
19. Rosen PP, Kimmel M, Ernsberger D. Mammary angiosarcoma. The prognostic significance of tumor differentiation. Cancer. 1988;62(10):2145-2151.
    doi
20. Kaklamanos IG, Birbas K, Syrigos KN, Vlachodimitropoulos D, Goutas N, Bonatsos G. Breast angiosarcoma that is not related to radiation exposure: a comprehensive review of the literature. Surg Today. 2011;41(2):163-168.
    doi pubmed
21. Toesca A, Spitaleri G, De Pas T, Botteri E, Gentilini O, Bottiglieri L, Rotmentsz N, et al. Sarcoma of the breast: outcome and reconstructive options. Clin Breast Cancer. 2012;12(6):438-444.
    doi pubmed
22. Barrow BJ, Janjan NA, Gutman H, Benjamin RS, Allen P, Romsdahl MM, Ross MI, et al. Role of radiotherapy in sarcoma of the breast—a retrospective review of the M.D. Anderson experience. Radiother Oncol. 1999;52(2):173-178.
    doi
23. McGowan TS, Cummings BJ, O'Sullivan B, Catton CN, Miller N, Panzarella T. An analysis of 78 breast sarcoma patients without distant metastases at presentation. Int J Radiat Oncol Biol Phys. 2000;46(2):383-390.
    doi
24. Penel N, Bui BN, Bay JO, Cupissol D, Ray-Coquard I, Piperno-Neumann S, Kerbrat P, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol. 2008;26(32):5269-5274.
    doi pubmed
25. Silverman LR, Deligdisch L, Mandeli J, Greenspan EM. Chemotherapy for angiosarcoma of the breast: case report of 30-year survival and analysis of the literature. Cancer Invest. 1994;12(2):145-155.
    doi pubmed
26. Kotton DN, Muse VV, Nishino M. Case records of the Massachusetts General Hospital. Case 2-2012. A 63-year-old woman with dyspnea and rapidly progressive respiratory failure. N Engl J Med. 2012;366(3):259-269.
    doi pubmed
27. Saunders ND, Marshall JS, Anderson RC. A case of chest wall angiosarcoma associated with breast implants. J Thorac Cardiovasc Surg. 2007;134(4):1076-1077.
    doi pubmed
28. Cao Y, Panos L, Graham RL, Parker TH 3rd, Mennel R. Primary cutaneous angiosarcoma of the breast after breast trauma. Proc (Bayl Univ Med Cent). 2012;25(1):70-72.
29. Deapen DM, Brody GS. Cancer risk among cosmetic breast implant patients: an update of the Los Angeles study. Plast Reconstr Surg. 2012;129(3):575e-576e.
    doi pubmed

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

World Journal of Oncology is published by Elmer Press Inc.